This two-day meeting has been purposely designed to facilitate collaboration and attract attendance from multiple stakeholders including KOL, investigators, academia, pharma, providers and regulators. The conference will examine the latest research and development in pathogenesis, diagnosis and treatment of the disease. As well as exceptional speaker presentations the meeting features 10 roundtable discussions. Each is led by an expert to provide you with a unique opportunity to debate the issues in areas such as the regulatory challenges for FDA approval, NASH and Diabetes and Preclinical models, to name just four.